导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.98% | 3998/4773 |
| 近一周 | -2.67% | 4130/5465 |
| 近一月 | -2.88% | 1984/5421 |
| 近一季 | -2.52% | 1404/5231 |
| 近半年 | -4.63% | 2888/4920 |
| 近一年 | -16.46% | 3829/4394 |
| 近两年 | 30.48% | 2258/2954 |
| 近三年 | 9.95% | 1754/2253 |
| 成立以来 | 9.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.24% 4705/4961 |
9.23% 2492/5312 |
- - |
- - |
| 2025 | 3.75% 3098/4813 |
-7.09% 3421/3635 |
4.48% 750/4076 |
11.45% 3160/4524 |
-4.10% 3395/4813 |
| 2024 | 28.89% 143/3463 |
-5.01% 1824/2808 |
-8.61% 2254/3014 |
43.06% 25/3129 |
3.78% 765/3463 |
| 2023 | 3.94% 251/2656 |
4.16% 1035/2280 |
-2.92% 709/2385 |
7.68% 27/2515 |
-4.55% 1089/2655 |
| 2022 | -26.11% 1368/2207 |
-18.67% 1372/1919 |
2.02% 1379/2016 |
-16.17% 1410/2113 |
6.22% 382/2208 |
| 2021 | -3.51% 908/1822 |
-15.08% 1186/1255 |
7.06% 705/1330 |
4.40% 354/1466 |
1.66% 843/1822 |
| 2020 | 19.61% 732/1250 |
-10.75% 803/1028 |
9.69% 784/1067 |
20.44% 53/1164 |
1.43% 1030/1184 |
| 2019 | 46.64% 132/1092 |
49.02% 8/754 |
-7.06% 542/804 |
-4.36% 767/850 |
10.70% 106/918 |
| 2018 | -24.30% 321/834 |
- - |
- - |
- - |
-1.56% 15/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证全指证券公司ETF VS. 长安沪深300非周期A(740101) |